Skip to content
ClinCalc Pro
Menu
Sympathomimetic (alpha + beta agonist)

Adrenaline (epinephrine)

Brand names: EpiPen, Emerade, Jext

Adrenaline (epinephrine) is an endogenous catecholamine used in emergency care, principally in cardiac arrest and as a vasopressor in shock, and intramuscularly in anaphylaxis.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Anaphylaxis: 0.5 mg (500 micrograms) intramuscularly — 0.5 mL of adrenaline 1 mg/ml (1:1000)
Route: Intramuscular — anterolateral aspect of the middle third of the thigh
Frequency: 'If necessary, this dose may be repeated several times at 5-minute intervals according to blood pressure, pulse and respiratory function'
⚠ SCOPE — THIS DRAFT COVERS THE PAGE'S PRIMARY INDICATION AND ROUTE ONLY: intramuscular adrenaline for anaphylaxis. VERBATIM UK SPC §4.2 (Adults): 'The usual dose is 0.5 mg (0.5ml of adrenaline 1mg/ml (1:1000)).' 'The intramuscular (IM) route is recommended by the EU Resuscitation Council as the most appropriate for most individuals who have to give adrenaline to treat an anaphylactic reaction.' 'The best site for IM injection is the anterolateral aspect of the middle third of the thigh.' 'The subcutaneous route for adrenaline is not recommended for treatment of an anaphylactic reaction as it is less effective.' NOT COVERED BY THIS BUNDLE: (a) the CARDIAC ARREST dose currently shown on the page (1 mg IV every 3–5 min) — neither fetched source contains any cardiac arrest regimen; source it separately before republishing that figure. (b) The NEBULISED route listed on the page. (c) IV/infusion dosing for anaphylaxis — the UK SPC states only that 'Intravenous administration of adrenaline for anaphylaxis requires the use of a 1:10,000 adrenaline solution' and that the IV route 'must be used with extreme caution and is best reserved for specialists familiar with IV use of adrenaline'; it gives no IV dose in the fetched text. DIFFERENT INDICATION, FOR AWARENESS ONLY — the US label in this bundle doses only hypotension associated with septic shock ('Titrate 0.05 mcg/kg/min to 2 mcg/kg/min to achieve desired blood pressure', diluted in 5% dextrose, into a large vein, adjusted every 10 to 15 minutes in increments of 0.05 mcg/kg/min to 0.2 mcg/kg/min, then weaned incrementally, such as by decreasing doses every 30 minutes over a 12- to 24-hour period); that is a different indication, route and product strength (0.1 mg/mL) from this page's primary use and must not be shown as the page dose. maxDose left empty deliberately: no dose ceiling is stated with an explicit maximum cue. Administration by a trained healthcare professional; do not give the 1 mg/ml (1:1000) solution intravenously.

Paediatric dose

Route: Intramuscular — anterolateral aspect of the middle third of the thigh
Frequency: May be repeated several times at 5–15 minute intervals according to blood pressure, pulse and respiratory function
Concentration: 1 mg/ml
Anaphylaxis only (matching the adult dose above). dosePerKg is null deliberately: the SPC's paediatric regimen is AGE-BANDED with fixed milligram doses, and its only per-kilogram figure (0.01 mg/kg) applies to infants under 6 months ONLY, so it is not valid across the paediatric range and must not drive a weight calculator. VERBATIM §4.2 'Paediatric population — The following doses of Adrenaline (Epinephrine) 1 mg/ml (1:1000) Solution for Injection are recommended: Over 12 years 0.5 mg IM (0.5ml 1mg/ml (1:1000) solution) [0.3 mg IM (0.3ml) if the child is small or pre-pubertal]; 6 - 12 years 0.3 mg IM (0.3ml 1mg/ml (1:1000) solution); 6 months - 6 years 0.15 mg IM (0.15ml 1mg/ml (1:1000) solution); Under 6 months 0.01mg/kg IM (0.01ml/kg 1mg/ml (1:1000) solution). If necessary, these doses may be repeated several times at 5 - 15 minutes intervals according to blood pressure, pulse and respiratory function. A small volume syringe should be used.' concentration = 1 because the source product is adrenaline 1 mg/ml (1:1000) — 1 mg per mL. maxDose left empty deliberately: no explicit maximum-dose cue. DO NOT give this 1:1000 strength intravenously. US label §8.4: 'Safety and effectiveness of epinephrine in pediatric patients with septic shock have not been established.' Verify any under-18 dose against a children's formulary before administration.

Dose adjustments

Renal

No renal dose adjustment is given in the fetched sections. §4.4 lists severe renal impairment among the conditions in which adrenaline should be used with caution, and notes that prolonged administration may induce metabolic acidosis, renal necrosis and tachyphylaxis. The US label adds (§5.5) that epinephrine constricts renal blood vessels, which may result in oliguria or renal impairment.

Hepatic

Not stated — the fetched UK SPC sections contain no hepatic impairment dosing statement.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients — but note the SPC's own qualifier, VERBATIM §4.3: 'Contraindications are relative as this product is intended for use in life-threatening emergencies.'
  • Use in fingers, toes, ears, nose, genitalia or buttocks owing to the risk of ischaemic tissue necrosis (§4.3)
  • Do not use if the solution is discoloured (§4.3)
  • Do not give the 1 mg/ml (1:1000) solution intravenously — §4.2/§4.4: intravenous administration of adrenaline for anaphylaxis requires a 1:10,000 (0.1 mg/ml) solution
  • Note: the US label in this bundle states 'CONTRAINDICATIONS None.' — the entries above are from the UK SPC and are the ones that apply in UK practice

Side effects

  • Cardiac: palpitations, tachycardia; in high dosage or in sensitive patients — cardiac dysrhythmia (sinus tachycardia, ventricular fibrillation/cardiac arrest), acute angina attacks and risk of acute myocardial infarction (§4.8)
  • Vascular: pallor, coldness of the extremities; in high dosage or in sensitive patients — hypertension (with risk of cerebral haemorrhage) and vasoconstriction, for example cutaneous, in the extremities or kidneys (§4.8)
  • Nervous system: headache, tremors, dizziness, syncope; in patients with Parkinsonian syndrome adrenaline increases rigidity and tremor (§4.8)
  • Psychiatric: anxiety, nervousness, fear, hallucinations (§4.8)
  • Metabolic: hyperglycaemia, hypokalaemia, metabolic acidosis (§4.8)
  • Gastrointestinal: nausea, vomiting (§4.8)
  • Respiratory: dyspnoea (§4.8)
  • Eye: mydriasis (§4.8)
  • General: sweating, weakness; repeated local injections may produce necrosis at sites of injection as a result of vascular constriction (§4.8)
  • All the above are listed at 'Frequency not known' in the SPC — the occurrence of undesirable effects depends on the sensitivity of the individual patient and the dose involved
  • US label §6 additionally lists, from infusion use: supraventricular tachycardia, ventricular arrhythmias, myocardial ischaemia, myocardial infarction, limb ischaemia, pulmonary oedema, extravasation and tissue necrosis, chest pain, hypoglycaemia/hyperglycaemia, insulin resistance, lactic acidosis, stroke, central nervous system bleeding, paraesthesia and renal insufficiency

Monitoring

  • VERBATIM §4.2: 'The patient should be monitored as soon as possible (pulse, blood pressure, ECG, pulse oximetry). This will help monitor the response to adrenaline.'
  • §4.4: 'This product is for emergency use only and medical supervision of the patients is necessary after administration.'
  • Blood glucose — §4.4: 'Adrenaline may cause or exacerbate hyperglycaemia, blood glucose should be monitored, particularly in diabetic patients.'
  • Inspect the injection site — repeated local administration may produce necrosis at the sites of injection (§4.4)
  • US label §5.1: 'Because individual response to epinephrine may vary significantly, monitor blood pressure frequently and titrate to avoid excessive increases in blood pressure.' §5.4 (IV infusion use): check the infusion site frequently for free flow to avoid extravasation and local necrosis

Clinical monograph

How it works

It is a potent agonist at alpha- and beta-adrenergic receptors, producing vasoconstriction, increased myocardial contractility and heart rate, and bronchodilation.

Prescribing in practice

  • Different clinical situations require very different concentrations and routes, so the correct strength must be confirmed against the indication, as confusion between intramuscular anaphylaxis and intravenous cardiac-arrest preparations can be fatal.
  • In cardiac arrest it is given intravenously or intraosseously during CPR per the resuscitation algorithm; as a peripheral vasopressor infusion it risks extravasation and tissue necrosis.
  • Effects are exaggerated in patients on non-selective beta-blockers or tricyclic antidepressants and it may provoke arrhythmias and severe hypertension.

Monitoring

Continuous ECG, blood pressure and, for infusions, invasive arterial and central access monitoring with frequent checks of the infusion site are required.

Counselling the patient

  • Confirm the indication-specific concentration and route before administration.
  • Give vasopressor infusions through a central line where feasible to limit extravasation injury.
  • Document timing of doses against the resuscitation cycle.

Evidence & guidelines

Adrenaline is recommended in Resuscitation Council UK advanced life support algorithms for cardiac arrest and as a first-line agent in anaphylaxis.

Reference: Resuscitation Council UK 2021; NICE CG134; MHRA DSU on auto-injectors; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.